Product
Deferasirox
Aliases
Deferasirox DT formulation, Deferasirox granule formulation, Exjade, ICL670
Name
Deferasirox
INN Name
Deferasirox
FDA Approved
Yes
5 clinical trials
5 organizations
7 indications
2 documents
Indication
Transfusion-dependent AnemiaIndication
HemochromatosisIndication
Myelodysplastic SyndromesIndication
Transfusion-dependent HemachromatosisIndication
Thalassemia MajorIndication
Sickle Cell DiseaseClinical trial
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron OverloadStatus: Completed, Estimated PCD: 2018-05-31
Clinical trial
Identification of Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients Undergoing a Hematopoietic Stem Cell Transplant (HSCT)Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.Status: Withdrawn, Estimated PCD: 2017-01-01
Clinical trial
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)Status: Completed, Estimated PCD: 2008-10-01
Clinical trial
Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron OverloadStatus: Completed, Estimated PCD: 2023-09-30
Organization
Ascend Laboratories, LLCDocument
DailyMed Label: DeferasiroxOrganization
Xiromed, LLCOrganization
Cipla USA Inc.Organization
Dr. Reddy's Laboratories Inc.Document
DailyMed Label: DeferasoroxOrganization
Novadoz Pharmaceuticals LLC